HealthDay on MSN10h
Breathing Dirty Air Might Raise Eczema RisksCases of the autoimmune skin condition eczema appear to rise in areas most plagued by air pollution, new research shows.
The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
The following is a summary of “Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic ...
The two companies have been working together since 2017, and, in 2021, they agreed to collaborate on NM26, a bispecific ...
Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback